We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
+34.99%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$292M
AUM Growth
-$19.9M
Cap. Flow
-$72.1M
Cap. Flow %
-24.64%
Top 10 Hldgs %
96.78%
Holding
22
New
1
Increased
–
Reduced
1
Closed
3

Top Buys

Rank Stock Value
1
SPRB
Spruce Biosciences
SPRB
+$3.34M

Top Sells

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$72.3M
2
OCGN icon
Ocugen
OCGN
+$16K
3
SLNO
Soleno Therapeutics
SLNO
+$2

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
1
Vaxcyte
PCVX
$7.81B
$100M 34.21%
4,168,718
– –
VERA icon
2
Vera Therapeutics
VERA
$2.3B
$63.1M 21.57%
2,960,231
– –
HLVX
3
DELISTED
HilleVax
HLVX
$31.4M 10.74%
1,838,486
– –
ACET icon
4
Adicet Bio
ACET
$85.2M
$30M 10.26%
132,212
– –
VRNA
5
DELISTED
Verona Pharma
VRNA
$25.1M 8.58%
2,457,500
– –
PHAT icon
6
Phathom Pharmaceuticals
PHAT
$708M
$15.9M 5.44%
1,435,106
– –
OKUR
7
OnKure Therapeutics
OKUR
$154M
$6.95M 2.38%
207,396
– –
JSPR icon
8
Jasper Therapeutics
JSPR
$21M
$4.44M 1.52%
562,856
– –
NCNA
9
NuCana
NCNA
$5.49M
$3.4M 1.16%
667
– –
EFTR
10
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
$2.73M 0.93%
192,885
– –
PRTK
11
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$2.68M 0.91%
1,041,131
– –
SPRB
12
Spruce Biosciences
SPRB
$118M
$2.47M 0.85%
+23,900
New +$3.34M
SLNO
13
DELISTED
Soleno Therapeutics
SLNO
$2.01M 0.69%
1,201,506
-1
-0% -$2
SIEN
14
DELISTED
Sientra, Inc.
SIEN
$1.07M 0.37%
167,359
– –
CBAY
15
DELISTED
Cymabay Therapeutics
CBAY
$457K 0.16%
131,036
– –
XCUR icon
16
Exicure
XCUR
$10.2M
$439K 0.15%
56,327
– –
MTEM
17
DELISTED
Molecular Templates, Inc.
MTEM
$150K 0.05%
13,333
– –
SYRE icon
18
Spyre Therapeutics
SYRE
$8.54B
$127K 0.04%
9,620
– –
OBSV
19
DELISTED
ObsEva SA Ordinary Shares
OBSV
$13K ﹤0.01%
87,999
– –
OCGN icon
20
Ocugen
OCGN
$416M
– –
-7,111
Closed -$16K
SRRA
21
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
– –
-1,314,127
Closed -$72.3M

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q3 2022 Portfolio in Review

As of Q3 2022, Abingworth held 22 positions worth $292M, down 6.4% from $312M the previous quarter. Its ten largest holdings account for 97% of the portfolio.

Abingworth withdrew a net $72.1M in Q3 2022, closing 3 positions and reducing 1 holding. Its most notable exit was Sierra Oncology, Inc. Common Stock, an estimated $72.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Abingworth opened a new position in Spruce Biosciences worth $2.47M.

  • Abingworth's largest Q3 2022 buy was Spruce Biosciences: 23,900 shares worth $2.47M.
  • Abingworth's biggest Q3 2022 reduction was Soleno Therapeutics, cutting an estimated $2.
  • Abingworth fully exited Sierra Oncology, Inc. Common Stock in Q3 2022, selling an estimated $72.3M.
  • Abingworth's ten largest holdings make up 97% of its $292M portfolio in Q3 2022.
  • Abingworth opened 1 new position and closed 3 in Q3 2022.
  • Abingworth's portfolio value fell 6.4% quarter-over-quarter to $292M.

Based on Abingworth's 13F filing for Q3 2022, filed 10 Nov 2022.